Composite Endpoints In Fibromyalgia Subject Of Dueling Citizen Petitions
Executive Summary
In trying to convince FDA to take Cypress Biosciences and Forest Laboratories' fibromyalgia drug Savella (milnacipran) off the market, the advocacy group Public Citizen has set itself the difficult task of arguing the agency out of its established policy of accepting clinical trials with composite endpoints as proof of efficacy against the disease.
You may also be interested in...
Sleep Claim For Jazz Fibromyalgia Drug Falls On Lack Of Distinction
If Jazz's sodium oxybate is approved to treat fibromyalgia, it will go to market without a sleep claim to differentiate it from competitors
Office Of New Drugs Reorganization Should Better Balance Workload, FDA Says
CDER's Office of New Drugs reorganizes as rheumatology moves from analgesics to join allergy.
Savella's Secret? "Unknown Factor" Could Be Key To Symptom Relief
The effect of Forest’s fibromyalgia therapy Savella (milnacipran) on a composite responder endpoint in Phase III did not correspond to the results for individual components of that endpoint, an "unusual finding" that the reviewing FDA division director suggested could result from the drug’s effect on an "unknown factor."